FOLR1 and anemia: In the phase I STRO-002-GM1 study (NCT03748186), luvelta showed remarkable antitumor activity in recurrent ovarian cancer with FRα expression > 25%, with manageable toxicity (neutropenia, arthralgia, anemia) [106].